Clinical Trial Update: CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of CY-503 for chemotherapy-refractory metastatic colorectal cancer has been terminated; no results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• CY-503

Snippet

Sponsor: Cytavis Biopharma GmbH | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED